KZIA — Kazia Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.10m
- -$0.44m
- AU$0.11m
- 16
- 30
- 80
- 36
Annual income statement for Kazia Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | R2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.2 | 0.002 | 0.023 | 2.32 | 0.114 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.1 | 25.4 | 20.8 | 29.4 | 24.1 |
| Operating Profit | -8.91 | -25.4 | -20.7 | -27 | -24 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.91 | -25.4 | -20.7 | -27 | -22.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.42 | -25 | -20.5 | -26.8 | -20.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.42 | -25 | -20.5 | -26.8 | -20.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.42 | -25 | -20.5 | -26.8 | -20.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.87 | -9.44 | -6.15 | -0.51 | -0.031 |